Opus Three is a Life Sciences Consulting Firm focused on scientific and clinical strategies for drug and diagnostic development with an emphasis on personalized medicine. 

Our experience in regulatory requirements and our understanding of payers’ needs allows us to provide a unique mix of services that integrate scientific and clinical needs with regulatory and reimbursement considerations into actionable, real-world based strategies.

We work with clients in a hands-on fashion and support them from conception to commercialization.  We not only help clients develop successful approaches but also translate them by providing expertise in e.g. writing regulatory submissions and clinical protocols, including working with IRBs, patient recruitment, clinical site management, and other services needed to build, conduct, and expand a successful health care and life sciences business.

Felix W. Frueh, PhD
Executive Partner

Dr. Felix Frueh is a respected thought leader in personalized medicine with twenty years of R&D, management, and policy experience.  He founded Opus Three, LLC in 2012 after spending several years at the FDA and in the payer environment working closely with the pharmaceutical and diagnostic industry.

Dr. Frueh is also Co-Founder and CEO of Intellos Health, LLC., a new diagnostic business focused on the development of affordable tests for the identification of patients requiring confirmatory testing to receive appropriate therapies.  

Prior, he was Chief Scientific Officer at Human Longevity, Inc. and Entrepreneur-in-Residence at Third Rock Ventures.  Dr. Frueh was President of the Medco Research Institute, leading the PBM’s research initiatives in health economics and outcomes research after having formed Medco’s personalized medicine R&D organization.  Prior to Medco, he was the first Associate Director for Genomics at the FDA, where he oversaw the development and implementation of policies around biomarker qualification and companion diagnostics.  

Dr. Frueh is a Board member at Enterome Biosciences, Ariana Pharmaceuticals, Intellos Health, and CredibleMeds, Inc., and also served on the Board of the Personalized Medicine Coalition.  He is a Fellow of the American College of Clinical Pharmacology and was a faculty member at Georgetown University in Washington, DC and at the University of North Carolina.  Dr. Frueh received his education at Stanford University and the University of Basel in Switzerland, where he graduated magna cum laude in biochemistry. 


Julia Ortega McEachern, PA, MHS
Associate Partner

Julia McEachern is an Associate Partner at Opus Three.  Over twenty-five years, she has honed her background in research and patient care to assist clients in the design and conduct of clinical programs and research studies, emphasizing on utilizing data for targeted patient populations and results oriented interventions.

Julia has worked nationally with numerous healthcare integrated systems to develop approaches to implementing Accountable Care Organizations (ACOs), Clinical Programs, Research Trial Management, and also programs for under- and over-utilization of medication and healthcare resources.  Her data management, payer, and research experience includes work with Ingenix (now Optum), United Health Group, Aetna, Medco, and more recently, Blue Shield of California.  She was also the Head of Alliance Management at Human Longevity, Inc.

Julia attributes her passion for helping individuals with chronic disease from her experience for over twelve years as a physician assistant in Internal Medicine and Geriatrics.  She began her research career at Social and Scientific Systems in Rockville, MD with the AIDS Clinical Trials Group (ACTG) and at the Henry M. Jackson Foundation for the Advancement of Military Medicine where she participated on the Walter Reed Army Institute Investigational Review Board.  She received her Physician Assistant and Master's degrees in Health Science from Duke University in Durham, NC and her Bachelor of Arts degree from Spelman College in Atlanta, GA.


Ernest Hsu, MBA
Sr. Research Associate

Ernest Hsu joined Opus Three in April 2016 and currently serves as a Senior Research Associate in the company.  Prior to Opus Three, Ernest worked at Roka Bioscience, where he led microbiology efforts in the laboratory for various Roka Listeria assays.  Previously, he held positions of increasing roles and responsibilities while at The Salk Institute of Biological Studies and at AltheaDx.  Aside from his R&D experience, Ernest brings skills in the development of GLP level SOPs, QC protocols and reporting, as well as client and customer interactions to Opus Three.

Ernest received his Master of Business Administration from the WP Carey School of Business at Arizona State University, and his B.S. in Biochemistry & Cell Biology from the University of California at San Diego.